Kornimate/medical-research-clean huggingface dataset:
comparison of ventro-cephalic to dorso-caudal translatoric glides in management of cervicogenic headache

Conditions: Cervicogenic Headache

Summary: this study is a randomised control trial and the purpose of this study is to compare ventro-cephalic to dorso-caudal translatoric glides in management of cervicogenic headache.

participants will be recruited into their respective groups using a coin toss method.cervicogenic headache will be assesed using international classification of headache disorders, 3rd edition: a- any headache fulling criterion c. b- clinical and/or imaging evidence of lesion or disorder in cervical spine or soft tissues of neck that can cause headache. c- evidence of cause of headache demonstrated by at least 2 of these: 1. headache has developed in temporal relation to the onset of the cervical disorder or lesion. 2. headache has significantly improved or resolved in parallel with improvement in cervical lesion or disorder. 3. cervical range of motion is reduced, and headache is made significantly worse by provocative maneuvers. 4. headache is abolished following anaesthetic blocked of cervical structure. d- not better accounted for by another ichd-3 diagnosis. ceh subject selection is based on clinical criteria, however anaesthetic blockades is not used as a criterion.

Eligibility criteria:
inclusion criteria: * • age 18 to 44 years old * both male and female a- any headache fulling criterion c. b- clinical and/or imaging evidence of lesion or disorder in cervical spine or soft tissues of neck that can cause headache. c- evidence of cause of headache demonstrated by at least 2 of these: 1. headache has developed in temporal relation to the onset of the cervical disorder or lesion. 2. headache has significantly improved or resolved in parallel with improvement in cervical lesion or disorder. 3. cervical range of motion is reduced, and headache is made significantly worse by provocative maneuvers. 4. headache is abolished following diagnostic blocked of cervical structure. d- not better accounted for by another ichd-3 diagnosis exclusion criteria: * 1- tension-type headaches and migraine 2- history of vertigo or dizziness 3- already taking manual therapy treatment 4- prior surgery to the head and neck 5- trauma
efficacy and safety of anakinra in acute respiratory distress syndrome

Conditions: Acute Respiratory Distress Syndrome

Summary: acute respiratory distress syndrome (ards) is a life-threatening condition characterized by acute respiratory failure with hypoxemia, noncardiogenic or non-fluid overload pulmonary edema, bilateral diffuse opacities on chest radiograph in the presence of a predisposing factor. in ards there is activation of the inflammatory cascade which is very intense and persistent in the severe types. it was highlighted that the inflammatory cytokines in patients with ards or sepsis is similar to that observed in covid-19 positive patients. emerging therapies include immunomodulation and the administration of mesenchymal stem cells for the modulation of lung repair through the release of cytokines and growth factors that modulate the local inflammatory response. regardless of the cause of ards, the severity of the inflammatory state and fibroproliferative evolution have been shown to be independent predictors of survival and ventilator dependence. patients suffering from severe forms of ards in fact require prolonged mechanical ventilation, which exposes them to ventilator-associated pneumonia (vap) and the onset of multiorgan insufficiency. the hyperinflammatory state underlying ards predisposes to pulmonary fibroproliferation, which in turn increases susceptibility to ventilator dependence and increases the risk of mof and death. for this reason, the rationale in the use of anakinra is to limit the inflammatory process of ards as early as possible, avoiding the progression of lung damage.


Eligibility criteria:
inclusion criteria: * patients admitted to intensive care unit diagnosed within 48 hours of moderate-severe ards (pao2/fio2 \< 200, peep ≥ 5 cmh2o) and requiring intubation and mechanical ventilation; * berlin clinical criteria for definition of ards: onset within 1 week of initial lesion or new or worsening respiratory symptoms, bilateral opacities not fully explained by effusions, lobar or lung collapse or nodules, respiratory failure not fully explained by heart failure or fluid overload * ards-like clinical-laboratory profile, defined by at least one of the following criteria: * high plasma levels of inflammatory biomarkers (e.g. il-6 \> 80 pg/ml, crp \> 250 mg/l) * dependence on vasopressors (of any type and at any dosage for at least one hour of treatment) * reduction of bicarbonatemia (\ 4 mmol/l) * informed consent for participation in the study * negative swab for covid-19. exclusion criteria: * pregnant or lactating patients; * hypersensitivity to the active substance or to any of the excipients or to proteins derived from escherichia coli; * concomitant treatment with anti-tnf-alpha or other biotechnological agent; * neutropenia (neutrophils \< 1.5 x 109/l); * pre-existing malignancies; * moderate to severe renal insufficiency, creatinine clearance \< 60 ml/minute.

Keywords: il-1 anakinra acute respiratory distress syndrome lung
early rehabilitation after total hip replacement

Conditions: Osteoarthritis, Hip

Summary: the purpose of this study is to determine whether supervised progressive resistance training is effective in the early phase after total hip replacement. the investigators hypothesise that 10 weeks of supervised, progressive resistance training immediately after discharge will lead to increased functional performance, muscle strength and muscle power compared to standard rehabilitation consisting of home-based exercise.

after total hip replacement (thr) surgery there is a documented deficit in muscle strength and functional performance. there is a lack of evidence concerning the effectiveness of postoperative physiotherapy and training, however a few small studies have shown promising effect of resistance training. the present study will provide new and important knowledge concerning the effect of different rehabilitation strategies after thr. this might lead to a change in the rehabilitation regimes and faster and better recovery after thr surgery.

Eligibility criteria:
inclusion criteria: * total hip replacement for osteoarthrosis * living within 30 km from the hospital * motivated to attend training 2 times/week in 10 weeks * reduced functional ability measured as: hoos score \< 67 * written informed consent exclusion criteria: * comorbidities such as cancer, neuromuscular diseases, heart diseases etc. * cognitive impairment * body mass index \> 35 * resurfacing prosthesis * scheduled additional prosthetic surgery in lower extremity within 6 months

Keywords: total hip replacement rehabilitation resistance training
ipaces v3 mci nia protocol copied for ipaces v4 pd ninds

Conditions: Parkinson's Disease; PD; Mild Cognitive Impairment; MCI

Summary: the primary purpose of this study is to attempt to replicate and extend promising pilot findings regarding the cognitive benefits of in-home neuro-exergaming with ipaces (interactive physical and cognitive exercise system v3) for persons with mild cognitive impairment (mci), to evaluate effects for persons with parkinson's disease (pd). participants will include persons with pd, and potentially, also their co-residing partner, who will exercise at home or accessible location, 3-5 times per week for at least 6 months, with follow-up one month after the main intervention. all participation is "remote" (completed at home, or location of choice), utilizing either one's own equipment ("bring-your-own-devices" byods: pedaler, phone/tablet, smart-watch) or some equipment which may be supplied by the grant-funded study and shipped directly to the home; all study measures are completed remotely (e.g., via phone app, website, biometric device, videoconference, email, snail mail, etc.).

a specific aim is to evaluate the effects of ipaces for persons with parkinson's disease, while also examining the potentially unique contribution of combining mental and physical exercise in an interactive way: "pedal-to-play" (ipaces), as compared with non-interactive, but simultaneous: "pedal-while-play" (pace).

Eligibility criteria:
inclusion criteria: 1. 50 years of age or older 2. meets criteria for mci (per site staff/md/neuropsychologist and confirmed by study-administered montreal cognitive assessment; moca; score = between 16-26, non-inclusive; milani, 2018) 4. available for participation for one year (tablet surveys, videoconference evaluations) 5. willing and able to exercise 3-5 times per week for at least 6 months 6. can pedal an under-table elliptical 7. can read off of a small tablet screen 8. proficient in english (speaking and reading for completion of interview, surveys, game); spanish language option anticipated soon 9. can participate in testing and read and operate tablet touch screen (adequate hearing, vision, speech) 10. written approval from primary care physician and cardiologist (if applicable) to participate in exercise for this study 11. can provide informed consent exclusion criteria: 1. already exercising at recommended levels (45 min of moderate intensity aerobic exercise 5-7x/wk) 2. significant history of cardiovascular problems 3. significant history of stroke 4. significant history of memory problems (e.g., dementia/alzheimer's) 5. significant history of other neurological condition (e.g., seizures, etc.) 6. significant uncontrolled tremor such that would interfere with touch-screen use required throughout the study (surveys, game-play, etc.) 7. not prone to cybersickness (e.g., "car sickness" or problems with "screen time") 8. cannot provide informed consent (i.e., when phone screened with the impaired decision making capacity screen)

Keywords: parkinson exercise exergame physical activity neuro-exergaming neuropsychological cognitive dual-task interactive executive function
post market study of parietene™ ds composite mesh in ventral hernia repair

Conditions: Ventral Hernia

Summary: a multi-center post-market single arm prospective study of parietene™ ds composite mesh in subjects undergoing ventral hernia repair to confirm its clinical safety and performance in the short (1, 3 months), mid (12 months) and long term (24 months)

a multi-center post-market single arm prospective study of parietene™ ds composite mesh in subjects undergoing ventral hernia repair to confirm its clinical safety and performance in the short (1, 3 months), mid (12 months) and long term (24 months) 125 male or female adults subjects will be enrolled in a minimum of 4 usa sites who are undergoing elective ventral hernia repair (primary or incisional)

Eligibility criteria:
inclusion criteria: * preoperative inclusion criteria 1. subject has provided informed consent 2. subject is ≥18 years of age (at the time of consent) 3. subject is undergoing elective ventral hernia repair (primary or incisional) with intraperitoneal mesh placement exclusion criteria: * preoperative exclusion criteria 1. bmi \> 45 kg/m2 2. subject is undergoing emergency surgery 3. subject is pregnant or planning to become pregnant during study participation period 4. subject is unable or unwilling to comply with the study requirements or follow-up schedule 5. subject has comorbidities which, in the opinion of the investigator, will not be appropriate for the study or the subject has an estimated life expectancy of less than 6 months 6. the subject has participated in another investigational drug or device research study within 30 days of enrollment 7. subject has a parastomal hernia * intra-operative exclusion criteria 1. subject's hernia repair is in a contaminated or infected site (cdc wound class 2-4) as assessed by the investigator(s) 2. subject is undergoing "bridging" repair technique with the mesh placed in an "inlay" position 3. surgeon is unable to completely remove existing mesh from prior surgery 4. surgeon overlays 2 meshes 5. subject receives any mesh other than parietene™ ds composite mesh
acute effect of continuous positive airway pressure in heart failure

Conditions: Heart Failure

Summary: acute effects of cpap on diastolic function in patients with compensated heart failure (chf) are unknown. the investigators hypothesized that acutely cpap improves diastolic function, which is associated with increases exercise tolerance. objective: to evaluate the acute effects of cpap on functional capacity and diastolic indices of patients with chf. this is a randomized trial including 44 patients with compensated heart failure (functional classes ii or iii, nyha). patients will be allocated in cpap(cpap with 10cmh2o) or simulated cpap (null pressure) after computed randomization, in a 1:1 ratio. all subjects shall complete a 6-minute walk test (6mwt) before and after cpap (30 minutes; 10 cm h2o pressure). doppler-echocardiogram will be performed before and at the end of cpap. wilcoxon or paired t tests were used to compare results, with significance level at p \< 0.05.


Eligibility criteria:
inclusion criteria: * functional class ii or iii (nyha)heart failure * agreement to participate in the study * absence of acute exacerbation of dyspnea * intact upper airway exclusion criteria: * valvular heart disease * chest pain or unstable angina * acute myocardial infarction in the prior month * uncontrolled hypertension * atrial fibrillation or other arrhythmias * acute infection * orthopedic limitations * intolerance to cpap mask
rituximab in treating patients with multiple myeloma

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Summary: rationale: monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them. purpose: phase ii trial to study the effectiveness of the monoclonal antibody rituximab in treating patients with multiple myeloma that is newly diagnosed.

objectives: i. evaluate the role of rituximab in inducing apoptosis of malignant plasma cells in patients with multiple myeloma. ii. evaluate the role of this regimen in improving the response rate to melphalan and prednisone in these patients. iii. determine whether the regimen decreases residual disease in these patients. iv. evaluate the toxic effects of this regimen in these patients. outline: patients receive rituximab iv every week for 4 weeks. treatment is repeated every 6 months for six courses. treatment may be discontinued after four courses if uncontrolled infection occurs. patients also receive oral melphalan and prednisone for 4 days which begin after the first course of rituximab. treatment is repeated every 4-6 weeks for at least nine courses. projected accrual: approximately 40 patients will be accrued for this study within 12-24 months.

Eligibility criteria:
disease characteristics: histologically proven, newly diagnosed multiple myeloma eligible if pancytopenia related to multiple myeloma at least 50% plasma cells in the bone marrow or splenomegaly or plasma cell leukemia no solitary extramedullary plasmacytoma or plasma cell dyscrasia patient characteristics: age: not specified performance status: ecog 0-2 life expectancy: at least 3 months hematopoietic: if less than 50% plasma cells in bone marrow: wbc at least 2,500/mm3 or absolute neutrophil count at least 1,000/mm3 (greater than 500/mm3 if platelet count at least 75,000/mm3) platelet count greater than 45,000/mm3 (thrombocytopenia related to idiopathic thrombocytopenic purpura or vitamin b12 or folate deficiency allowed) hepatic: bilirubin no greater than 2 times upper limit of normal (uln) alt or ast less than 2 times uln (if greater than one third of liver involved, then no greater than 5 times uln) no severe hepatic disease renal: creatinine no greater than 2.0 mg/dl other: no severe infection requiring intravenous antibiotics not pregnant or nursing fertile patients must use effective contraception no prior malignancy within 5 years except for treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix no type i hypersensitivity or anaphylactic reactions to murine proteins or to any component of rituximab prior concurrent therapy: biologic therapy: no prior bone marrow transplantation concurrent sargramostim (gm-csf) allowed for severe, symptomatic neutropenia chemotherapy: at least 4 weeks since investigational drugs endocrine therapy: not specified radiotherapy: not specified surgery: not specified other: no concurrent use of investigational drugs or devices concurrent epoetin alfa allowed for anemia plasmapheresis allowed at study onset to treat renal failure

Keywords: stage i multiple myeloma stage ii multiple myeloma stage iii multiple myeloma
an efficiency of a moisturizer containing licochalcone a, l-carnitine and 1,2-decanediol with adapalene gel in acne

Conditions: Acne

Summary: acne is an inflammation of sebaceous glands and follicles. applying topical treatments such as adapalene gel may cause irritant adverse effects. hence, using a moisturizer is another way to protect or relieve this undesirable event. moisturizers that have anti-inflammatory property could reduce irritant effects, emergent from using topical treatment and also reduce severity of acne. research teams chose an adapalene gel to act as topical treatment for curing acne. it has anti-inflammatory and comedolytic effects and has fewer side effects than other groups of topical retinoic acids. however, peeling skin, redness skin, tingling sensation or itching sensation may occur if they are continually used for a long period. thus, for the purpose of studying the efficacy of moisturizer containing licochalcone a, l-carnitine and 1,2-decanediol in reducing irritant effect of using adapalene gel (licochalcone a has anti-inflammatory effect, l-carnitine decrease sebum production and 1,2-decanediol has anti-bacterial effect).

the investigators team research with patients by separate patients into 3 groups and compare among each other. in the first group use only adapalene gel, the second group use adapalene gel with moisturizer containing three substances mentioned above, and the last group use adapalene gel with placebo moisturizer. to compare outcomes among 3 groups, the investigators will measure degree of redness, scale, oily face, moist, number of acne, quality of life, and satisfaction after using moisturizer.

Eligibility criteria:
inclusion criteria: 1. age 18 years old or above 2. participants have to control the birth for example, condom method, intrauterine device method before participate in the research at least 1 month until 6 months after research finish. 3. being diagnosed acne vulgaris by dermatologist in mild to moderate degree based on investigators' global assessment scale of fda exclusion criteria: 1. use oral or injected antibiotics or other oral medicine treating acne for example, isotretinoin, oral contraceptives, or spironolactone group during 4 weeks before participate this research 2. have other active skin diseases at face during 2 weeks before participate the research 3. allergic to adapalene gel and moisturizer 4. have severe or uncontrolled underlying diseases 5. getting pregnant or during breast feeding 6. other types of acne(not acne vulgaris)

Keywords: acne moisturizer efficacy irritation
the effects of blackcurrant supplementation on eye health

Conditions: Eye Strain; Eye Fatigue

Summary: the purpose of this study is to evaluate the potential for supplementation with black currant to support eye health among otherwise healthy adult women who spend 6+ hours per day using digital screens.

women who are informed about the study and provide informed consent will be randomized to one of two groups: supplement and placebo. group assignment will be a 1:1 ratio to supplement (455mg of blackcurrant standardized to 50mg anthocyanins in 2 capsules/day) or placebo (2 capsules/day). outcomes will be assessed at baseline and again on day 70.

Eligibility criteria:
inclusion criteria: * female * age 30-60 * lives in the united states * employed full time in an online work environment or enrolled full time in an online learning environment (average of 6+ hours per day) * ability to understand study instructions * ability to provide informed consent * residence within 100 miles of the study center exclusion criteria: * low blood pressure * uncontrolled hypertension (i.e. systolic/diastolic blood pressure \> 140/90) * uncontrolled diabetes (i.e. fasting blood glucose \>180mg/dl) * any blood clotting disorder * ocular disease * best corrected visual acuity \<20/30 * cataracts * renal disease * active hepatitis or cirrhosis * acute or chronic infectious disease * pregnant * breastfeeding * currently trying to conceive * surgical or other invasive procedure planned within the intervention period

Keywords: black currant blackcurrant ribes nigrum digital eye fatigue eye health computer vision syndrome dietary supplement
protocol of assistance to patients with covid-19 submitted to treatment with hd-tdcs

Conditions: Coronavirus; COVID-19 Respiratory Infection

Summary: covid-19 has a variety of symptoms from asymptomatic respiratory dysfunction to death. considering the pathophysiology of sars-cov-2 and its relationship with the neuroimmune system, response, autonomic balance, musculoskeletal and respiratory and neuropsychiatric symptoms presented by patients, the investigators highlight the potential use of non-invasive neuromodulation methods to assess the effectiveness of treating patients with covid-19, as these techniques can be useful in the management of important clinical aspects in the functional recovery of individuals affected by the disease. the investigators intend to evaluate the effects of hd- tdcs to promote ventilatory weaning in patients admitted to the intensive care unit (icu) and to improve the respiratory performance of those hospitalized in nursing beds for treatment of covid - 19.


Eligibility criteria:
intensive care unit's inclusion criteria: patients of at least 18 years-old with a pcr-confirmed sars-cov-2 diagnosis and receiving mechanical ventilation at least 48 hours of meeting criteria for moderate to severe acute respiratory distress syndrome (ards), under weaning, were enrolled in this study. an ards diagnosis was made according to the berlin definition criteria. intensive care unit's exclusion criteria: patients were excluded if they had a condition that could prevent adequate performance of inspiratory muscle training (e.g., neuropathy or myopathy), pregnancy or active lactation, richmond agitation and sedation scale (rass) scores between -2 and + 1, glasgow coma scale (gcs) ≤ 8, consent refusal, and contraindications to brain stimulation (e.g., aneurysm clips).